NCT03004287 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03003520 A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma Status COMPLETED Phase PHASE2
NCT03000634 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy Status WITHDRAWN Phase PHASE2
NCT02992522 Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02986451 Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma Status WITHDRAWN Phase PHASE2
NCT02983097 Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP Status TERMINATED Phase PHASE1/PHASE2
NCT02969837 Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma Status COMPLETED Phase PHASE2
NCT02963610 Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT02954406 A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma Status TERMINATED Phase PHASE1
NCT02928419 Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q Status TERMINATED Phase PHASE2
NCT02921893 Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome Status COMPLETED Phase EARLY_PHASE1
NCT02918331 A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation Status COMPLETED Phase PHASE1
NCT02917941 A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma Status COMPLETED Phase PHASE2
NCT02916771 Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma Status COMPLETED Phase PHASE2
NCT02911142 Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02906332 Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) Status TERMINATED Phase PHASE2
NCT02903381 A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma Status COMPLETED Phase PHASE2
NCT02898259 Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma Status TERMINATED Phase PHASE1/PHASE2
NCT02897830 Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma Status TERMINATED Phase PHASE2